01672 ASCLETIS-B
- 1.290
- -0.050-3.73%
ASCLETIS-B News
歌禮製藥-B：二零二三年年報
Goli Pharmaceutical-B (1672.HK) 2023 Annual Results Announcement Comment: Losses narrowed sharply year over year, focus on multi-milestone events catalyzed
Recently, the company announced its 2023 annual results. During the reporting period, the company achieved operating income of 556.6 million yuan (+4.6% YoY), loss of about 145 million yuan (-54.0% YoY), and R&D expenses of 2.
Ascletis Discontinues Trials of FXR Agonist for Biliary Cholangitis, NASH and Hepatitis B Virus
Ascletis Pharma (HKG:1672) has decided not to proceed with further clinical trials of its farnesoid X receptor (FXR) agonist ASC42 for primary biliary cholangitis (PBC) indication, according to a fili
Kerry Pharmaceutical-B (01672.HK) Announces Strategic Decision on Farnesol X Receptor (FXR) agonist ASC42
On April 3, Gelonghui Pharmaceutical-B (01672.HK) announced a strategic decision on the farnesol X receptor (FXR) agonist ASC42. After thorough analysis of the ASC42 phase II clinical trial (ClinicAlt rials.gov: NCT05190523) data for primary biliary cholangitis (PBC), the company made a strategic decision not to continue clinical trials with ASC42 for PBC. The decision was based on efficacy and safety data from the 12-week phase II study, which included three ASC42 active treatment groups (5
Goli Pharmaceutical-B (01672.HK): 23 years of steady growth, focusing on differentiated innovation pipelines, deepening R&D in the MASH field
Incident: Goli Pharmaceuticals Announces 2023 Results: Revenue Up 4.6% Year Over Year, Loss Narrowed 54% Year On Year; Significant Progress Has Been Made in Multiple R&D Pipelines: ASC41-NASH, ASC40-NASC40-LIT
Goli Pharmaceutical-B (1672.HK): Innovative drug development has achieved excellent results and sufficient cash reserves
Event: The company announced its 2023 results. Revenue for 2023 increased 4.6% to RMB 56.6 million. Revenue from ritonavir products increased by about 49.4 million yuan, and losses from 3.15 in '22
Goli Pharmaceutical-B (01672) announced its 2023 annual results, with revenue of about 56.6 million yuan, an increase of 4.6% over the previous year
Goli Pharmaceutical-B (01672) announced the results for the year ended December 31, 2023. The Group's revenue increased from 2...
Goli Pharmaceutical-B (01672.HK) annual loss reduced to 145 million yuan
Gelonghui, March 25 | Goli Pharmaceutical-B (01672.HK) announced that for the year ended December 31, 2023, the company's revenue increased 4.6% from approximately RMB 54.1 million in the previous year to approximately RMB 56.6 million. The Group's total revenue (including revenue and other revenue and revenue) increased by 45.2% from approximately RMB 166.1 million in the previous year to approximately RMB 241.2 million. The Group's loss for the year decreased from RMB 314.8 million in the previous year to RMB 144.7 million in the same year, mainly due to (i) the increase in product sales revenue
ASCLETIS-B: ANNUAL RESULTS OF ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2023
A major favorable raid, and the 1.6 trillion innovative drug sector is booming!
The advantage suddenly “smashed” into the pharmaceutical sector!
Hong Kong Stock Announcement Nuggets | SF Express Tongcheng expects net profit from continuing operations to be no less than 60 million yuan in 2023
ESR's subsidiary interests in the proposed sale of ARA's private equity business are expected to achieve revenue of about 50 million US dollars; Glory Pharmaceutical-B announced that it will present the final results of the Phase II study of the FASN inhibitor ASC40 to treat acne at the 2024 American Academy of Dermatology (AAD) annual meeting
Ascletis Announces Poster Presentation of Phase II Study Final Results of FASN Inhibitor ASC40 for Treatment of Acne at 2024 AAD Annual Meeting
HANGZHOU and SHAOXING, China, March 11, 2024 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") today announces the poster presentation of Phase II study final results of ASC40, a first-in-
Cully Pharmaceutical-B (01672) announced that it will present the final results of the FASN inhibitor ASC40 to treat acne phase II at the 2024 American Academy of Dermatology (AAD) Annual Meeting
Cully Pharmaceutical-B (01672) issued an announcement. The board of directors announced the 2024 US Skin to be held in San Diego, USA...
Announcement Highlights | NIO's Q4 revenue increased 6.5% year on year to 17.103 billion yuan; Great Wall Motor's February sales increased 4.12% year on year
China Electric Power's combined total electricity sales volume in January was 10.3482 million megawatt-hours, an increase of 41.15% over the previous year; Shanghai Pharmaceutical: Norepinephrine bitartrate injection passed the generic drug consistency evaluation.
Goli Pharmaceutical-B (01672) cancelled 32.63 million shares repurchased on March 5
Goli Pharmaceutical-B (01672) issued an announcement to cancel 32.63 million shares and repurchase them on March 5, 2024...
Guojin Securities: Chronic Hepatitis B Cure Track has broad potential market space and continues to recommend companies that deploy long-acting interferons and related innovative drugs
The chronic hepatitis B cure track is one of the tracks that the trip continues to be optimistic about and recommended. Clinical cure for chronic hepatitis B has now entered a new stage from early exploration to international recognition to rapid and in-depth development.
Goley Pharmaceutical-B (01672.HK) plans to hold a board meeting on March 25 to approve annual results
On February 23, Ge Longhui Pharmaceutical-B (01672.HK) issued an announcement. The board of directors meeting will be held on March 25, 2024 (Monday) to consider and approve the annual results and announcements of the company and its subsidiaries for the year ended 31 December 2023, and to consider recommending payment of a final dividend (if any).
ASCLETIS-B: NOTICE OF BOARD MEETING
Repurchase Collection on February 22 | Yum China, Kuaishou-W, etc. bought back one after another, of which Yum China spent HK$36.6715 million
According to documents disclosed by the Hong Kong Stock Exchange on February 23, $Yum China (09987.HK) $, $Kuaishou-W (01024.HK) $, etc. repurchased shares. ① $Yum China (09987.HK) $ repurchased 104,800 common shares on February 21, involving an amount of HK$36.6715 million. The repurchase price per share ranged from HK$334.2 to HK$321.2. The cumulative number of securities repurchased during the year (since the adoption of the ordinary resolution) is 1,067,000 shares, accounting for 0.24% of the number of shares issued when the ordinary resolution was passed. ② $
Goli Pharmaceutical-B (01672.HK) spent HK$908,000 to buy back 480,000 shares on February 22
On February 22, Gelonghui Pharmaceutical-B (01672.HK) announced that on February 22, it spent HK$908,000 to buy back 480,000 shares at a price of HK$1.9-1.87 per share.
Analysis
Price Target
No Data
